Nuvation Bio Inc.

Nuvation Bio Inc. (NYSE: NUVB) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics in oncology. The company entered the public markets through a business combination with Panacea Acquisition Corp. II, a SPAC sponsored by EcoR1 Capital that completed its initial public offering in 2021; the de-SPAC merger closed in February 2022. Nuvation Bio filed this Form 8-K current report with the SEC on September 5, 2024, continuing its active disclosure obligations as a publicly listed oncology-focused biotechnology company. For complete filings history, deal metrics, and ongoing company data, sign up for full access at SpacDesk.